Literature DB >> 16536663

Elevated positive mood: a mixed blessing for abstinence.

Neal Doran1, Bonnie Spring, Belinda Borrelli, Dennis McChargue, Brian Hitsman, Raymond Niaura, Donald Hedeker.   

Abstract

The present study, a secondary analysis of published data, assessed (a) the influence of initial positive mood (PM) on smoking cessation and (b) whether smokers low in PM benefited from fluoxetine versus placebo for cessation. Euthymic adult smokers (N = 103) received 10 weeks of cessation treatment. Analyses showed a Time x PM interaction, indicating that higher baseline PM predicted decreased abstinence during treatment but increased abstinence afterward, mediated by time to dropout. Dichotomous initial PM interacted with drug, suggesting a benefit of fluoxetine for low-PM smokers. Results indicate that lower pretreatment PM may inhibit long-term cessation. Smokers with lower baseline PM may benefit from treatment that increases PM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16536663     DOI: 10.1037/0893-164X.20.1.36

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  20 in total

1.  Isolating the role of psychological dysfunction in smoking cessation: relations of personality and psychopathology to attaining cessation milestones.

Authors:  Adam M Leventhal; Sandra J Japuntich; Megan E Piper; Douglas E Jorenby; Tanya R Schlam; Timothy B Baker
Journal:  Psychol Addict Behav       Date:  2012-05-28

Review 2.  Applying the tripartite model of anxiety and depression to cigarette smoking: an integrative review.

Authors:  Katherine J Ameringer; Adam M Leventhal
Journal:  Nicotine Tob Res       Date:  2010-10-29       Impact factor: 4.244

3.  Relations between anhedonia and smoking motivation.

Authors:  Adam M Leventhal; Andrew J Waters; Christopher W Kahler; Lara A Ray; Steve Sussman
Journal:  Nicotine Tob Res       Date:  2009-07-01       Impact factor: 4.244

4.  Changes in Affect and Drinking Outcomes in a Pharmacobehavioral Trial for Alcohol Dependence.

Authors:  Michelle D Vaughan; Joshua N Hook; J Nile Wagley; Don Davis; Christina Hill; Bankole A Johnson; J Kim Penberthy
Journal:  Addict Disord Their Treat       Date:  2012-03

5.  Longitudinal associations between smoking and affect among cancer patients using varenicline to quit smoking.

Authors:  Allison J Carroll; Kristine Kim; Andrew Miele; Matthew Olonoff; Frank T Leone; Robert A Schnoll; Brian Hitsman
Journal:  Addict Behav       Date:  2019-04-03       Impact factor: 3.913

6.  Positive Affect as a Predictor of Smoking Cessation and Relapse: Does It Offer Unique Predictive Value among Depressive Symptom Domains?

Authors:  Jaimee L Heffner; Kristin E Mull; Jennifer B McClure; Jonathan B Bricker
Journal:  Subst Use Misuse       Date:  2017-11-21       Impact factor: 2.164

7.  Post-trauma anhedonia is associated with increased substance use in a recently-traumatized population.

Authors:  Negar Fani; Jahnvi Jain; Lauren A Hudak; Barbara O Rothbaum; Kerry J Ressler; Vasiliki Michopoulos
Journal:  Psychiatry Res       Date:  2020-01-09       Impact factor: 3.222

8.  The association of positive emotion and first smoking lapse: An ecological momentary assessment study.

Authors:  Christine Vinci; Liang Li; Cai Wu; Cho Y Lam; Lin Guo; Virmarie Correa-Fernández; Claire A Spears; Diana S Hoover; Paul E Etcheverry; David W Wetter
Journal:  Health Psychol       Date:  2017-07-20       Impact factor: 4.267

9.  A cross-lagged path analysis of five intrapersonal determinants of smoking cessation.

Authors:  Yessenia Castro; Miguel Ángel Cano; Michael S Businelle; Virmarie Correa-Fernández; Whitney L Heppner; Carlos A Mazas; David W Wetter
Journal:  Drug Alcohol Depend       Date:  2014-01-31       Impact factor: 4.492

10.  Psychological mediators of bupropion sustained-release treatment for smoking cessation.

Authors:  Danielle E McCarthy; Thomas M Piasecki; Daniel L Lawrence; Douglas E Jorenby; Saul Shiffman; Timothy B Baker
Journal:  Addiction       Date:  2008-09       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.